pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

Sponsored

Beyond weight loss: How obesity trial design is evolving

For many years, body weight sat at the centre of obesity drug development.

News

Most doctors in UK think AI training is inadequate

A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but training is lacking.

Market Access

The expanding role of early-phase trials in modern drug deve...

Digital

The future of feasibility: AI-driven site selection & protoc...

AI can help sponsors identify higher-potential sites, improve enrolment predictability, and accelerate study startup timelines.

News

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

Featured Content

Digital

The future of feasibility: AI-driven site selection & protoc...

AI can help sponsors identify higher-potential sites, improve enrolment predictability, and accelerate study startup timelines.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Patients

pharmaphorum podcast Episode 262, Lee-Ann Farrell, Johnson & Johnson

Towards a healthier world: Momentum in UK health system tran...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Most doctors in UK think AI training is inadequate

A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but training is lacking.

News

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

Views & Analysis

Digital

The future of feasibility: AI-driven site selection & protoc...

AI can help sponsors identify higher-potential sites, improve enrolment predictability, and accelerate study startup timelines.

R&D

Sponsored

Beyond weight loss: How obesity trial design is evolving

For many years, body weight sat at the centre of obesity drug development.

Patients

ASCO 26: Three cancer survivors share lessons for the field

In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Oncology

ASCO 26: Precision medicine takes a village, with Carolyn So...

In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.

Patients

Towards a healthier world: Momentum in UK health system tran...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson.

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

Partner Content

Press Releases

Partner Content

Inizio Launches Intelligent Congress to Turn Event Investmen...

Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress

Event

Partner Content

17th World ADC San Diego | October 12-15, 2026

The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes

Event

Partner Content

6th Rare & Genetic Kidney Disease Drug Development Summit

The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc

Press Releases

Partner Content

Navigating Change: Key Industry Insights at PHARMAP 2026

PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content